AlphAIAlphAI — Financial news for AI agents
investing.comSEP 142 min read$DFTX

Definium Therapeutics stock jumps on positive trial results

Definium Therapeutics (DFTX) shares rose 20% after reporting positive Phase 3 trial results for DT120 ODT in treating generalized anxiety disorder. The study met primary and secondary endpoints, showing a 5.1-point reduction in anxiety scores. The drug was well-tolerated, with a safety profile consistent with prior trials. The company plans to file for FDA approval in 2027.

Original reporting
investing.com
Published Sep 14, 2026, 11:32 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 11:44 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$DFTX
Bullish
high confidence
Mentioned
$DFTX
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$DFTXBullishMed
01

Why it matters

The trial's success is likely to drive short-term stock gains and long-term valuation uplift pending NDA approval.

02

Market read

Trial success could catalyze a broader rally in mental‑health biotech stocks and attract partnership interest.

03

What to watch

Competition from other anxiety treatments and the need for successful NDA filing could temper upside.

Relevance 9/10Novelty 9/10Timing: today

Background

Definium Therapeutics announced positive topline Phase 3 results for its DT120 ODT anxiety drug.

Company-level read

Ticker impact

$DFTXBullishHigh confidence
Context

Positive Phase 3 trial results for DT120 ODT in generalized anxiety disorder, driving a 20% stock rise.

Expected impact

Further upside possible as market digests data and anticipates NDA filing.

Evidence & confidence

Phase 3 success is a material catalyst; stock already jumped, but additional upside remains as regulatory path progresses.

Market effects

Sector

Positive GAD trial may boost biotech sector focused on anxiety therapeutics.

Regional

U.S. biotech stocks could see uplift from the news.

Global

Potential interest from global pharma partners and investors in anxiety drug pipelines.

Counterpoint

What could challenge this read

The 20% rally may be overstated if later data reveal safety concerns or regulatory hurdles.

Key entities

  • company
    Definium Therapeutics

    Biotech firm developing anxiety disorder treatments.

  • drug
    DT120 ODT

    Orally disintegrating tablet for generalized anxiety disorder.

Read at source← All news

Also covered by

2 outlets

Related articles

SEP 14
$DFTXMedAI 9/10

Definium's DT120 ODT Achieves Significant Anxiety Improvement In Phase 3 Trial; Stock Up

Definium Therapeutics (DFTX) reported positive Phase 3 trial results for DT120 ODT in treating generalized anxiety disorder, meeting primary and secondary endpoints. The study showed significant reduction in HAM-A scores with a 5.1-point placebo-adjusted improvement. The company plans to submit a New Drug Application in early 2027. DFTX stock rose 3.07% to $38.89 on Friday and is up 13.40% in pre-market trading.

rttnews.com2 min
SEP 14
$DFTXHighAI 9/10

Why is Definium Therapeutics stock surging today?

Definium Therapeutics (DFTX) stock surged 20.7% in pre-market trading after its Phase 3 trial of DT120 ODT for generalized anxiety disorder met its primary endpoint. The company has also received FDA Breakthrough Therapy designation for DT120 in major depressive disorder. Analysts had previously assigned Buy or Strong Buy ratings, with price targets above current levels. The stock is nearing its 52-week high of $49.70, up from a low of $8.77.

investing.com2 min
SEP 13
$DFTXLow

Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026

Definium Therapeutics (DFTX) will host a webcast on September 14, 2026, to discuss topline results from its Phase 3 Panorama study of DT120 ODT for generalized anxiety disorder. The study enrolled 245 participants across 32 centers, with primary endpoints focused on changes in HAM-A and CGI-S scores. Definium Therapeutics is a Nasdaq-listed biopharmaceutical company developing psychiatric and neurological disorder treatments.

owensoundsuntimes.com1 min
AUG 19
$DFTXHighAI 9/10

Definium Therapeutics (DFTX) Could Be 22% Undervalued On Positive Phase 3 Voyage Results

Definium Therapeutics (DFTX) reported positive Phase 3 results for DT120 ODT in treating generalized anxiety disorder, meeting primary and secondary endpoints. Shares have surged 12.88% in 7 days and 121.27% in 90 days, with a 1-year return of 391.80%. Analysts estimate revenue of $320.2M by July 2029 and a 1.7% profit margin, suggesting a 22.3% undervaluation at $46.18 vs. a $59.47 fair value.

simplywall.st2 min